SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending following a positive analyst upgrade that highlights the company's progress in regulatory pathways and validates the therapeutic potential of its lead candidate, Sonelokimab. Investors are actively discussing the stock's significant long-term growth prospects, the potential for a strategic buyout, and the upcoming clinical data readouts that are expected to solidify the drug's position as a best-in-class treatment.

Fermi, Inc. engages in the development of energy infrastructure. It intends to develop an energy and data center development campus to support the needs of to-be-built AI infrastructure. The company was founded by Rick Perry, Toby Neugebauer and Griffin Perry on January 10, 2025 and is headquartered in Amrillo, TX.

Fermi Inc

Fermi LLC

Fermi LLC is trending as investors closely monitor the development of Project Matador and anticipate a potential tenant announcement, following reports of a substantial equipment financing facility and strategic partnerships. The community remains actively divided, with many debating the company's timeline for operational capacity and power grid integration, while others highlight the massive short interest and potential for a significant upside breakout once a definitive data center tenant is secured.

Sigma Lithium Corp. engages in the producing of a lithium property. It focuses its project in Minas Gerais. The firm also plans to build a world-class commercial-scale lithium concentration plant. The company was founded on June 8, 2011 and is headquartered in Sao Paulo, Brazil.

Sigma Lithium Corporation

Sigma Lithium is generating significant market interest as investors closely monitor reports of a major spodumene supply deficit and rising lithium futures. While bullish community sentiment is fueled by expectations of strong 2026 growth and potential production capacity increases, the stock remains a battlefield between retail investors anticipating a breakout and short sellers targeting concerns over operational timelines and liquidity.

Americas Gold & Silver Corp. engages in the acquisition, exploration, development, and exploration of mineral resource properties. It operates through the following segments: Cosalá Operations, Galena Complex, Relief Canyon, and Corporate and Other. The Cosalá Operations segment operates in Mexico. The Galena Complex and Relief Canyon segments focuses on the United States. The company was founded by Peter Jude Hawley on May 12, 1998 and is headquartered in Toronto, Canada.

Americas Gold and Silver Corp

Americas Gold and Silver Corporation

Americas Gold and Silver is trending as investors monitor the company's recent acquisition of the Crescent Silver Mine and its strategic positioning in the domestic antimony market. Market participants are actively discussing the stock's high institutional ownership and potential for rapid growth as the company aims to quadruple silver production while benefiting from record-high precious metal prices.

United Therapeutics Corp. is a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening conditions. Its products include Adcirca, Orenitram, Remodulin, TYVASO, and Unituxin. The company was founded by Martine A. Rothblatt on June 26, 1996 and is headquartered in Silver Spring, MD.

United Therapeutics Corp

United Therapeutics is trending following the TETON-1 study's success in meeting its primary efficacy endpoint for treating idiopathic pulmonary fibrosis, driving investor optimism regarding the company's pipeline expansion. The community is actively discussing the drug's potential market impact, the competitive landscape involving inhaled treprostinil treatments, and broader implications for the company's valuation as it maintains its strong commercial presence.

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is currently trading near multi-year lows, fueling intense debate among retail traders regarding whether the stock is an oversold value opportunity ahead of earnings or a value trap facing structural headwinds in China. While some investors are pointing to insider buying and historical support levels as a signal to accumulate, others remain skeptical, citing ongoing inventory issues, declining margins, and stiff competition from newer athletic brands.

Viridian Therapeutics, Inc. is a biopharmaceutical company that develops medicines for autoimmune and rare diseases. It uses antibody discovery and protein engineering to create new therapies. The company is advancing late-stage IGF-1R therapies for thyroid eye disease (TED) and developing a potential TSHR-targeted treatment for TED and Graves’ disease. In addition, it is developing FcRn inhibitors, including VRDN-006 and VRDN-008, for multiple autoimmune diseases. The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Waltham, MA.

Viridian Therapeutics Inc

Viridian Therapeutics is facing intense scrutiny following the release of elegrobart REVEAL-1 phase 3 data, which triggered a significant pre-market stock decline despite meeting primary endpoints. Investors are actively debating the drug's competitive positioning against current standard-of-care treatments, with community sentiment divided between those viewing the pullback as a buying opportunity and skeptics questioning its long-term viability without head-to-head trial data.

Roma Green Finance Ltd. is a holding company, which engages in the provision of environmental, social and governance, sustainability, and climate change related advisory services through its subsidiaries. Its services include corporate and risk advisory, sustainability strategy services, climate risk advisory, ESG reporting services, and sustainable finance. The company was founded in 2018 and is headquartered in Hong Kong.

Roma Green Finance Ltd - Ordinary Shares - Class A

Roma Green Finance Ltd

Roma Green Finance is trending following the board's authorization of a 100 million dollar share repurchase program, sparking intense community debate over its potential to boost shareholder value versus concerns about the company's long-term financial health. Traders are closely monitoring the stock's significant volatility and trading volume, with many actively discussing whether the buyback will support a sustained upward trend or if the stock remains vulnerable to typical small-cap pump-and-dump dynamics.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is currently trending as investors focus on the potential for new partnership announcements following institutional briefings at the Jefferies summit, while the community remains divided over management's performance and the threat of a proxy fight. Traders are closely watching high short interest and institutional accumulation, with many expecting the company's Matrix-M technology platform to serve as a key catalyst for future valuation growth.

Boston Scientific Corp. engages in the development, manufacture, and marketing of medical devices that are used in interventional medical procedures. It operates through the MedSurg and Cardiovascular segments. The MedSurg segment includes Endoscopy, Urology, and Neuromodulation. The Cardiovascular segment consists of Cardiology and Peripheral Interventions. The company was founded by John E. Abele and Pete Michael Nicholas on June 29, 1979 and is headquartered in Marlborough, MA.

Boston Scientific Corp.

Boston Scientific (BSX) is trending following positive data from the Champion-AF clinical trial, which confirmed the safety and efficacy of the Watchman FLX device compared to standard anticoagulants. Community discourse remains highly active, balancing excitement over the company's clinical innovation with skepticism driven by ongoing litigation, recent analyst price target adjustments, and the broader macro-driven rotation within the medtech sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$ACV $VRTS Virtus Diversified Income &amp; Convertible Fund Discloses Sources of Distribution – Section 19(a) Notice
https://www.stocktitan.net/news/ACV/virtus-diversified-income-amp-convertible-fund-discloses-sources-of-cesd7bkop2aq.html

Virtus Diversified Income & Convertible Fund (ACV) disclosed its monthly distribution of $0.18 per share, payable on April 29, 2024. The Fund aims to maintain a consistent distribution level from net investment income and realized capital gains. Shareholders should be aware that any shortfall in income may result in a return of capital.

Stocktitan

Virtus Diversified Income & Convertible Fund Discloses Sources of Distribution - Section 19(a) Notice

StockTitan

Virtus Investment Partners Inc

AllianzGI Diversified Income & CNV FD

 Virtus Diversified Income & Convertible Fund Discloses Sources of Distribution – Section 19(a) Notice
